AVPR2 and Hyponatremia: Appropriate endocrinology advice is crucial in treating cancer-related hyponatremia and discuss about starting tolvaptan, an oral elective vasopressin V2-receptor antagonist that is approved for euvolemic and hypervolemic hyponatremia [92].